资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants

Vaccine. 2026-01; 
Ninaad Lasrado, Annika Rössler, Isabella McConnell, Katherine Molloy, Ritobhas Bhowmik, Christine Happle, Ruoran Guan, Katherine McMahan, Juliana Pereira, Jinyan Liu, Erica Borducchi, Liping Wang, Krishna Shah, Bridget Wixted, Metodi V Stankov, Alexandra Dopfer-Jablonka, Ai-Ris Y Collier, Georg M N Behrens, Dan H Barouch
Products/Services Used Details Operation
Peptide Library Services CD4+ and CD8+ T cell responses were quantitated by pooled peptide-stimulated intracellular cytokine staining (ICS) assays. Peptide pools contained 15 amino acid peptides overlapping by 11 amino acids spanning the SARS-CoV-2 WA1/2020, BA.5, XBB.1.5, and JN.1 spikes (21st Century Biochemicals and GenScript). Get A Quote

摘要

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to evolve five years after the initial outbreak. Although mRNA vaccines encoding the JN.1 and KP.2 Spike proteins were authorized in fall 2024, it remains unclear whether vaccine updates will be necessary for variants containing antigenically closely related Spike proteins. In this study, we evaluated the immunogenicity of JN.1 and KP.2 mRNA boosters in participants from Germany and the United States, respectively. Both vaccines induced robust and similar neutralizing antibody responses against JN.1, KP.2, and other globally relevant variants such as LP.8.1.1 and NB.1.8.1. These data suggest that updating the vaccine formulation to closely r... More

关键词

Booster; COVID-19; JN.1; KP.2; mRNA.
Article Link >